Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors.

Radiation exposure is a possible predisposing factor for monoclonal gammopathy of undetermined significance (MGUS), but the association has been uncertain. We investigated the relationship between radiation exposure and MGUS prevalence by using data from the M-protein screening for Nagasaki atomic bomb survivors between 1988 and 2004. Radiation exposure was assessed by exposure distance from the hypocenter and exposure radiation dose. We computed prevalence ratios (PRs) and the 95% confidence intervals (CIs) adjusting for exposure age and sex. A total of 1082 cases of MGUS were identified from 52 525 participants. MGUS prevalence was significantly higher in people exposed at distance within 1.5 km than beyond 3.0 km (PR, 1.4; 95% CI, 1.1-1.9) among those exposed at age 20 years or younger, but it was not found among those exposed at age 20 years or older. MGUS prevalence was also significantly higher in people exposed to more than 0.1 Gy than those exposed to less than 0.01 Gy (PR, 1.7; 95% CI, 1.0-2.8) among those exposed at age 20 years or younger. Thus, people exposed at younger age exhibited a significantly high risk of MGUS when exposed to a high radiation dose. There was no clear association between radiation exposure and the malignant progression of MGUS. Further detailed analysis is needed.

[1]  M. Tomonaga,et al.  Waldenström's macroglobulinemia in a 10-year stable IgG monoclonal gammopathy of undetermined significance. , 2009, Leukemia research.

[2]  Henry T. Lynch,et al.  Familial myeloma. , 2008, The New England journal of medicine.

[3]  L. Brown,et al.  Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. , 2008, Blood.

[4]  Dale L Preston,et al.  Solid cancer incidence in atomic bomb survivors exposed in utero or as young children. , 2008, Journal of the National Cancer Institute.

[5]  J. Deddens,et al.  A comparison of two methods for estimating prevalence ratios , 2008, BMC medical research methodology.

[6]  M. Nakashima,et al.  Incidence of multiple primary cancers in Nagasaki atomic bomb survivors: Association with radiation exposure , 2007, Cancer science.

[7]  M. Tomonaga,et al.  Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan. , 2007, Mayo Clinic proceedings.

[8]  N. Munshi.  Monoclonal gammopathy of undetermined significance: genetic vs environmental etiologies. , 2007, Mayo Clinic proceedings.

[9]  B. Heinmiller,et al.  The 15-Country Collaborative Study of Cancer Risk among Radiation Workers in the Nuclear Industry: Estimates of Radiation-Related Cancer Risks , 2007, Radiation research.

[10]  S. Montoto,et al.  Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size. , 2007, Mayo Clinic proceedings.

[11]  M. Tomonaga,et al.  Late hematological effects in the atomic bomb survivors , 2007 .

[12]  H. Adami,et al.  Multiple myeloma: A review of the epidemiologic literature , 2007, International journal of cancer.

[13]  S. Vincent Rajkumar,et al.  Monoclonal gammopathy of undetermined significance , 2013, Radiopaedia.org.

[14]  E. Wright,et al.  Untargeted effects of ionizing radiation: implications for radiation pathology. , 2006, Mutation research.

[15]  R. Hoover,et al.  Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. , 2005, Blood.

[16]  T. Therneau,et al.  Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. , 2005, Blood.

[17]  Donna Spiegelman,et al.  Easy SAS calculations for risk or prevalence ratios and differences. , 2005, American journal of epidemiology.

[18]  N. Pearce,et al.  Further follow-up of New Zealand participants in United Kingdom atmospheric nuclear weapons tests in the Pacific , 1997, Cancer Causes & Control.

[19]  Charles Mw,et al.  Studies of mortality of atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality: 1950-1997. , 2003 .

[20]  E. Wright,et al.  Radiation-induced genomic instability and bystander effects: inter-related nontargeted effects of exposure to ionizing radiation , 2003, Oncogene.

[21]  H. Kaufmann,et al.  New insights into the pathophysiology of multiple myeloma. , 2003, The Lancet. Oncology.

[22]  E. Nakashima,et al.  Monoclonal gammopathy of undetermined significance in atomic bomb survivors: incidence and transformation to multiple myeloma , 2003, British journal of haematology.

[23]  C. Muirhead,et al.  Follow up of mortality and incidence of cancer 1952–98 in men from the UK who participated in the UK's atmospheric nuclear weapon tests and experimental programmes , 2003, Occupational and environmental medicine.

[24]  G. Morgan,et al.  Myeloma aetiology and epidemiology. , 2002, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[25]  N. Dainiak.  Hematologic consequences of exposure to ionizing radiation. , 2002, Experimental hematology.

[26]  C. Klersy,et al.  Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  P. L. Bergsagel,et al.  Multiple myeloma: evolving genetic events and host interactions , 2002, Nature Reviews Cancer.

[28]  Terry M Therneau,et al.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance. , 2002, The New England journal of medicine.

[29]  D. Richardson,et al.  A case control study of multiple myeloma at four nuclear facilities. , 2000, Annals of epidemiology.

[30]  P. Smith,et al.  CALENDAR , 1984, British Journal of Cancer.

[31]  R. Casale,et al.  Risk of monoclonal gammopathy of undetermined significance: A case‐referent study , 1996, American journal of hematology.

[32]  N. Kamada,et al.  Estimation of radiation doses for atomic-bomb survivors in the Hiroshima University Registry. , 1996, Health physics.

[33]  N. Weiss,et al.  Healthy screened bias in epidemiologic studies of cancer incidence. , 1996, Epidemiology.

[34]  E Cardis,et al.  Effects of low doses and low dose rates of external ionizing radiation: cancer mortality among nuclear industry workers in three countries. , 1995, Radiation research.

[35]  N. Dalager,et al.  Cancer mortality risk among military participants of a 1958 atmospheric nuclear weapons test. , 1995, American journal of public health.

[36]  P. Smith,et al.  Cancer mortality and morbidity among workers at the Sellafield plant of British Nuclear Fuels. , 1994, British Journal of Cancer.

[37]  R. Doll,et al.  Cancer mortality following X‐ray treatment for ankylosing spondylitis , 1994, International journal of cancer.

[38]  R. Doll,et al.  Mortality in a cohort of women given X‐ray therapy for metropathia haemorrhagica , 1994, International journal of cancer.

[39]  H. Dohy,et al.  Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. , 1994, Radiation research.

[40]  E. Gilbert,et al.  Mortality of workers at the Hanford site: 1945-1986. , 1993, Health physics.

[41]  R. Doll,et al.  Further follow up of mortality and incidence of cancer in men from the United Kingdom who participated in the United Kingdom's atmospheric nuclear weapon tests and experimental programmes. , 1988, BMJ.

[42]  Y. Okumura,et al.  Medical Database for the Atomic-Bomb Survivors at Nagasaki University , 1992 .

[43]  R. Hoover,et al.  Diagnostic x-ray procedures and risk of leukemia, lymphoma, and multiple myeloma. , 1991, JAMA.

[44]  D. Pierce,et al.  Allowing for random errors in radiation dose estimates for the atomic bomb survivor data. , 1990, Radiation research.

[45]  H. Kato,et al.  Cancer risk among atomic bomb survivors. The RERF Life Span Study. Radiation Effects Research Foundation. , 1990, JAMA.

[46]  N. Pearce,et al.  Follow up of New Zealand participants in British atmospheric nuclear weapons tests in the Pacific. , 1990, BMJ.

[47]  G. R. Petersen,et al.  Mortality of workers at the Hanford site: 1945-1981. , 1989, Health physics.

[48]  P Fraser,et al.  Radiation dose and second cancer risk in patients treated for cancer of the cervix. , 1988, Radiation research.

[49]  R. Doll,et al.  A summary of mortality and incidence of cancer in men from the United Kingdom who participated in the United Kingdom's atmospheric nuclear weapon tests and experimental programmes , 1988, British medical journal.

[50]  Eizo Tajima,et al.  US-Japan Joint Reassessment of Atomic Bomb Radiation Dosimetry in Hiroshima and Nagasaki (Final Report) , 1987 .

[51]  P G Smith,et al.  Mortality of workers at the Sellafield plant of British Nuclear Fuels. , 1986, British medical journal.

[52]  H. Tolley,et al.  A further update of the analysis of mortality of workers in a nuclear facility. , 1983, Radiation research.

[53]  M. Ichimaru,et al.  Multiple myeloma among atomic bomb survivors in Hiroshima and Nagasaki, 1950-76: relationship to radiation dose absorbed by marrow. , 1982, Journal of the National Cancer Institute.

[54]  R. Kyle,et al.  Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. , 1978, The American journal of medicine.

[55]  H. Akaike.  A new look at the statistical model identification , 1974 .